

2<sup>nd</sup> June, 2022

**BSE Limited**

Department of Corporate Relationship  
1<sup>st</sup> Floor, New Trade Ring, Rotunda Building  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
*Scrip Code: 524742*

**National Stock Exchange of India Ltd.,**

Department of Corporate Services  
Exchange Plaza, 5<sup>th</sup> Floor,  
C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
*Scrip Code: CAPLIPOINT.*

Dear Sir / Madam,

**Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions for the half year ended March 31, 2022.

This is for your kind information and records.

Thanking You,

Sincerely yours,

For **Caplin Point Laboratories Limited**

**Dinesh R G**

**Company Secretary**



**Disclosure of Related Party Transactions for the Half Year Ended 31st March 2022**

(Rs. In Crores)

| S.No | Details of the party (listed entity /subsidiary) entering into the transaction |                  | Details of the counterparty   |                  |   | Type of related party transaction                       | Value of the related party transaction as approved by the audit committee | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction |  | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments |      |        | Details of the loans, inter-corporate deposits, advances or investments |                   |        |                    |
|------|--|------------------|-------------------------------|------------------|---|---|---|--|---|--|---|------|--------|---|-------------------|--------|--------------------|
|      | Name   | PAN <sup>^</sup> | Name                          | PAN <sup>^</sup> | Relationship of the counterparty with the listed entity or its subsidiary |   |   |  | Opening balance as on 1st October 2021 Receivable/(Payable)           | Closing balance as on 31st March 2022 Receivable/(Payable) | Nature of indebtedness (loan/ issuance of debt/ any other etc.)   | Cost | Tenure | Nature (loan/ advance/ intercorporate deposit/ investment)              | Interest Rate (%) | Tenure | Secured/ unsecured |
| 13   | Caplin Point Laboratories Limited  |                  | Mr. Muralidharan D            |                  | Key Management Personnel  | Remuneration  | Not Applicable  | 0.25   | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |
|      |  |                  |                               |                  |   | Equity Shares Pursuant to employees stock option scheme |   | 0.39   | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |
| 14   | Caplin Point Laboratories Limited  |                  | Mr. Partheeban Vivek Siddarth |                  | Chief Operating Officer   | Remuneration  | Not Applicable  | 0.10   | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |
| 15   | Caplin Point Laboratories Limited  |                  | Mr. Dinesh R G                |                  | Key Management Personnel  | Remuneration  | Not Applicable  | 0.05   | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |
| 16   | Caplin Point Laboratories Limited  |                  | Mr. D P Mishra                |                  | Non-Executive Non-Independent Director                                    | Sitting Fees  | Not Applicable  | 0.06   | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |
| 17   | Caplin Point Laboratories Limited  |                  | Dr. K C John                  |                  | Independent Director  | Sitting Fees  | Not Applicable  | 0.12   | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |
| 18   | Caplin Point Laboratories Limited  |                  | Mr. D Sathyanarayanan         |                  | Independent Director  | Sitting Fees  | Not Applicable  | 0.08   | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |
| 19   | Caplin Point Laboratories Limited  |                  | Mr. V Thirumalai              |                  | Independent Director  | Sitting Fees  | Not Applicable  | 0.12   | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |
| 20   | Caplin Point Laboratories Limited  |                  | Mr. R Viswanathan             |                  | Independent Director  | Sitting Fees  | Not Applicable  | 0.04   | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |
| 21   | Caplin Point Laboratories Limited  |                  | Dr. C K Gariyali              |                  | Independent Director  | Sitting Fees  | Not Applicable  | 0.04   | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |
| 22   | Caplin Point Laboratories Limited  |                  | Caplin Onco Limited           |                  | Wholly owned Subsidiary   | Equity Investment*                                      | 125.00  | 24.96  | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |

<sup>^</sup> PAN Details are masked as the same are advised not to be displayed on the website of the Stock Exchanges

\* Investment to be made in one or more tranches

# Loan to be provided in one or more tranches